Tracked strategy
Biotech All-Star Tracker
as of Oct 25, 2026
These are the tracked strategy’s holdings and client-strategy returns. They do not establish this person’s own positions or profit.
| Security | Allocation | Unrealized P&L |
|---|---|---|
| KODKodiak Sciences Inc Common Stock | 12.1% | Not disclosed |
| ONCBeOne Medicines Ltd. American Depositary Shares | 6.2% | Not disclosed |
| ROIVRoivant Sciences Ltd. Common Shares | 5.8% | Not disclosed |
Only part of the portfolio is public · 16 additional holdings not published (75.9%)
Stock P&L requires a disclosed position cost basis and a dated valuation in the same currency. It is unrealized price P&L and excludes dividends and realized gains. Missing inputs stay undisclosed.
Published portfolio return
as of Oct 23, 2026 · Started Aug 20, 2026
- Last month
- +1.34%
- Since inception
- -11.05%
Performance methodology
The performance data presented reflects the aggregated results of actual client portfolios managed by the Registered Investment Adviser (RIA), based on the trading activity in the securities contained in the relevant portfolio over the specified period. If fewer than 10 clients are invested in the portfolio, the data represents the aggregate performance of all clients following this strategy. Performance figures are shown net of advisory fees, calculated using the applicable subscription fee and an assumed $50,000 account size. Because subscription fees are flat rather than asset-based, accounts smaller than $50,000 would experience a higher effective fee percentage and lower net performance, while larger accounts would experience a lower effective fee percentage. Actual investor outcomes can vary due to factors like brokerage support for fractional shares, account size, trade timing, fees, and taxes, and past performance should not be interpreted as a guarantee of future results or typical of all portfolios.